Who is sponsoring NCT00378443?

NCT00378443 is sponsored by Peking University.

What drugs are being tested in NCT00378443?

Interventions in NCT00378443: prednisone + Inhibace/Cozaar, Inhibace/Cozaar.

What condition does NCT00378443 study?

NCT00378443 studies Glomerulonephritis, IGA.

Is NCT00378443 still recruiting?

NCT00378443 is currently status unknown. Last updated 21 September 2006.

Last reviewed 2006-09-21 · How we verify

NCT00378443

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT

Status unknown NA Last updated 21 September 2006

What this trial tests

NA trial testing prednisone + Inhibace/Cozaar in Glomerulonephritis, IGA. Status unknown.

Timeline

1 January 2006

1 June 2007

Quick facts

Lead sponsor	Peking University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 January 2006
Estimated completion	1 June 2007

Drugs / interventions tested

prednisone + Inhibace/Cozaar — full drug profile →
Inhibace/Cozaar — full drug profile →

Conditions studied

Glomerulonephritis, IGA — all drugs for Glomerulonephritis, IGA →

Sponsor

Peking University

Who can join

Adults 16 to 65, any sex, with Glomerulonephritis, IGA. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Serum creatinine
24 hour urinary protein excretion

Sponsor's own description

IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. Both ACEi/ARB and steroid was found to be effective in slowing the rate of disease progression, but the use of steroid was restricted because of its side effects. However, there is no evidence from RCT on the question of whether combined use of steroid with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore undertook a randomized, multicenter study to investigate the efficacy and safety profile of combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of patients with IgAN.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunosuppressive agents for treating IgA nephropathy.
Natale P, Palmer SC, Ruospo M, Saglimbene VM, et al · · 2020 · cited 61× · PMID 32162319 · DOI 10.1002/14651858.cd003965.pub3
Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.
Jeyabalan A, Jhaveri KD, Bunke M, Briggs JA, et al · · 2025 · cited 2× · PMID 40493692 · DOI 10.1371/journal.pone.0323530

Verify or expand the search:

Other recruiting trials for Glomerulonephritis, IGA

Currently open trials in the same condition.

NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
NCT06797518 — Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN · Phase 2 · recruiting
NCT04663204 — A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropath · Phase 2 · active not recruiting

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00378443 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 21 September 2006

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00378443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing